secwatch.observer — SEC 8-K summary
======================================

Issuer:     Landos Biopharma, Inc. (—)
CIK:        0001785345
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-075991
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire Landos Biopharma for $20.42/sh cash plus up to $11.14/sh CVR
------------------------------------------------------------------------------

- Total upfront cash consideration ~$137.5M; CVR milestone of up to $75M for Phase 3 start of NX-13 in UC by March 2029.
- Landos stockholders holding ~57.6% of shares have agreed to vote in favor; deal expected to close Q2 2024.
- NX-13 is a first-in-class oral NLRX1 agonist currently in Phase 2 NEXUS trial for moderate-to-severe ulcerative colitis.
- CVRs are non-tradeable and contingent on initiating first Phase 3 trial for NX-13; no assurance milestone will be achieved.
- Termination fee of $7M payable by Landos under certain circumstances if deal fails or a superior proposal accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/0001193125-24-075991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785345/000119312524075991/d779916d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-075991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer